Tracer provides a software platform that transforms existing NGS sequencers and dPCR systems into tools for Minimal Residual Disease (MRD) detection. The platform offers vendor-agnostic integration, enabling labs to generate quantitative Tumor Fraction reports from raw sequencing data. This decentralizes MRD testing, providing high-sensitivity, tissue-free cancer monitoring with rapid turnaround times.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Monitoring molecular response and minimal residual disease (MRD) in cancer patients requires frequent, cost-effective, and highly sensitive assays. Conventional NGS-based circulating tumor DNA (ctDNA) assays often require large sample volumes and can be cost-prohibitive for longitudinal monitoring over multiple time points.
Solution
Tracer Biotechnologies offers an ultrasensitive, tumor-informed digital PCR assay specifically designed for longitudinal molecular response monitoring and MRD detection. The assay utilizes a personalized approach, leveraging existing biomarker data for initial tumor-informed assay design. This enables cost-effective monitoring with industry-leading sensitivity and specificity, even at low blood volumes, making it suitable for frequent measurements over the course of a study. The Tracer assay is available for both blood and urine samples, providing a non-invasive method for tracking changes in tumor fraction and detecting minimal levels of residual disease.
Target Audience
The primary target audience includes oncologists, clinical researchers, and pharmaceutical companies involved in cancer drug development and treatment monitoring.
Features
- Tumor-informed assay design using digital PCR for personalized monitoring
- Industry-leading sensitivity and specificity for accurate MRD detection
- Cost-effective fixed pricing for unlimited time points per patient
- Rapid turnaround time (sub-7 days) for timely clinical decision-making
- Low sample volume requirements compared to conventional NGS-based assays
- Compatibility with both blood and urine samples for non-invasive monitoring
- Quantitative measurement of molecular response and tumor fraction changes